case study: inadequately controlled polycythemia vera (pv)
Published 7 years ago • 3.2K plays • Length 17:25Download video MP4
Download video MP3
Similar videos
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
19:02
prognostication and initiation of therapy in polycythemia vera: do we have it right?
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
19:03
assessment of novel treatment options for patients with pv
-
5:07
case presentation #1
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
9:43
polycythemia vera: when to move from hydroxyurea to second-line therapy
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
23:39
expert perspectives: jak inhibitors for polycythemia vera
-
3:37
inadequately controlled polycythemia vera
-
13:49
“masked” polycythemia vera and polycythemia vera “in evolution”
-
21:43
hydroxyurea intolerance/resistance in polycythemia vera
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera
-
19:36
evolution of the assessment of clinical benefit in polycythemia vera
-
0:57
polycythemia vera case study - final thoughts on ruxolitinib
-
26:50
“masked” polycythemia vera: time to change who diagnostic criteria
-
18:50
jak inhibitors for et and pv: what have we learned so far?
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?